Position in CYTK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$290,926
-$351,752 QoQ
Shares Held
4,414
-72.4% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Derivatives in CYTK
reported options exposure · as of Mar 31, 2024CallValue
$0
CallShares
0
PutValue
$19,960,317
PutShares
284,700
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Graham Capital Management, L.P. holds $44,243,780 across 71 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
446,696 | $25,376,799 | |
| 2 | INCY |
Incyte Corp
|
15,632 | $1,772,043 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
16,717 | $1,325,490 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
22,114 | $862,667 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,256 | $679,123 | |
| 6 | ARVN |
Arvinas, Inc.
|
81,364 | $676,134 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
11,107 | $645,649 | |
| 8 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
92,277 | $575,808 |
All Filings in CYTK
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $290,926 | 4,414 | Shares | Sole | 2026-05-15 | |
| 2025-03-31 | $642,678 | 15,991 | Shares | Sole | 2025-05-15 | |
| 2024-06-30 | $417,131 | 7,699 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $19,960,317 | 284,700 | Put | Sole | 2024-05-15 | |
| 2024-03-31 | $232,274 | 3,313 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $23,769,603 | 284,700 | Put | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||